ImmunityBio announces NCCN Guidelines for Bladder Cancer to include Anktiva

ImmunityBio (IBRX) announced that the National Comprehensive Cancer Network has updated its 2026 NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer to include Anktiva in combination with Bacillus Calmette-Guerin for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary-only disease. This update expands previous NCCN clinical guideline recommendations, which included patients with BCG-unresponsive NMIBC with carcinoma in situ with or without papillary disease, to now also recognize patients with BCG-unresponsive NMIBC with papillary-only disease as candidates for treatment with Anktiva plus BCG. Both recommendations are Category 2A. The immunotherapy regimen is designed to activate natural killer cells and T cells and has demonstrated durable responses in clinical studies. The NCCN guideline reference to Anktiva for patients with BCG-unresponsive NMIBC with papillary-only disease reflects a use that is not included in the current FDA approved indication for Anktiva.